JP5601951B2 - Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition - Google Patents
Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition Download PDFInfo
- Publication number
- JP5601951B2 JP5601951B2 JP2010216051A JP2010216051A JP5601951B2 JP 5601951 B2 JP5601951 B2 JP 5601951B2 JP 2010216051 A JP2010216051 A JP 2010216051A JP 2010216051 A JP2010216051 A JP 2010216051A JP 5601951 B2 JP5601951 B2 JP 5601951B2
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- component
- water
- extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims description 90
- 239000000203 mixture Substances 0.000 title claims description 49
- 239000002537 cosmetic Substances 0.000 title claims description 25
- 239000013543 active substance Substances 0.000 claims description 24
- 150000003904 phospholipids Chemical class 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 150000001298 alcohols Chemical class 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 description 35
- 239000000284 extract Substances 0.000 description 29
- 235000014113 dietary fatty acids Nutrition 0.000 description 22
- 239000000194 fatty acid Substances 0.000 description 22
- 229930195729 fatty acid Natural products 0.000 description 22
- 239000012528 membrane Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000012071 phase Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 238000003860 storage Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 5
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000003702 sterols Nutrition 0.000 description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 229940056692 resinol Drugs 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- CMPDPBDUZTUXAD-UHFFFAOYSA-N [3-hydroxy-2-(16-methylheptadecanoyloxy)propyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC(C)C CMPDPBDUZTUXAD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 229940068939 glyceryl monolaurate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- ZXNAIPHYBVMMPY-KTKRTIGZSA-N 1-erucoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(O)CO ZXNAIPHYBVMMPY-KTKRTIGZSA-N 0.000 description 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 1
- FUTGDWNFCMWSJT-UHFFFAOYSA-N 2,3-bis(14-methylpentadecanoyloxy)propyl 14-methylpentadecanoate Chemical compound CC(C)CCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)C FUTGDWNFCMWSJT-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- XFBOJHLYDJZYSP-UHFFFAOYSA-N 2,8-dioxoadenine Chemical compound N1C(=O)N=C2NC(=O)NC2=C1N XFBOJHLYDJZYSP-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ZVTDEEBSWIQAFJ-KHPPLWFESA-N 2-hydroxypropyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C)O ZVTDEEBSWIQAFJ-KHPPLWFESA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 description 1
- QNJOVLAFLJQFBF-UHFFFAOYSA-N 2-octyldodecyl 16-methylheptadecanoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCCCCCCCCCC(C)C QNJOVLAFLJQFBF-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XCAKLCDEUPZJOI-UHFFFAOYSA-N 24-methylpentacosan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCCCCCCCCCO XCAKLCDEUPZJOI-UHFFFAOYSA-N 0.000 description 1
- ZVVIVHWMFKRBSY-UHFFFAOYSA-N 26-methylheptacosan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCCCCCCCCCCCO ZVVIVHWMFKRBSY-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 235000006667 Aleurites moluccana Nutrition 0.000 description 1
- 244000136475 Aleurites moluccana Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001072282 Limnanthes Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000123826 Lutjanus campechanus Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000183666 Nepsera aquatica Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- OWRMXHRUFYLLQP-UHFFFAOYSA-N [3-[2,3-bis(16-methylheptadecanoyloxy)propoxy]-2-hydroxypropyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C OWRMXHRUFYLLQP-UHFFFAOYSA-N 0.000 description 1
- YFCGDEUVHLPRCZ-UHFFFAOYSA-N [dimethyl(trimethylsilyloxy)silyl]oxy-dimethyl-trimethylsilyloxysilane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C YFCGDEUVHLPRCZ-UHFFFAOYSA-N 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229940105039 coconut extract Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- DMMXZLMYEUEJFT-UHFFFAOYSA-N ethyl 16-methylheptadecanoate Chemical compound CCOC(=O)CCCCCCCCCCCCCCC(C)C DMMXZLMYEUEJFT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 229940081618 glyceryl monobehenate Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、リポソーム含有組成物、並びに、該組成物を配合してなる皮膚用水溶性化粧料に関する。 The present invention relates to a liposome-containing composition and a water-soluble cosmetic for skin obtained by blending the composition.
リポソームとは、生体膜の主要構成成分であるリン脂質からなる脂質二重膜で構成された閉鎖小胞体である。従来から、皮膚バリア機能を改善する薬剤などをリポソームに内包させて皮膚用化粧料に配合し、皮膚への経皮吸収性を高める試みがなされている（例えば、特許文献１〜３を参照）。 Liposomes are closed vesicles composed of a lipid bilayer composed of phospholipids, which are the main constituents of biological membranes. 2. Description of the Related Art Conventionally, attempts have been made to increase the transdermal absorbability to the skin by encapsulating drugs that improve the skin barrier function in liposomes and blending them in skin cosmetics (for example, see Patent Documents 1 to 3). .
しかしながら、化粧水、エッセンス、ジェル製剤、水中油型乳化製剤などの連続相が水相である皮膚用水溶性化粧料に、水溶性の生理活性物質を内包させたリポソームを配合すると、リポソーム内から水溶性の生理活性物質が漏れ出し易く、本来のリポソームの機能を十分に発揮することができないといった問題がある。 However, when liposomes encapsulating water-soluble physiologically active substances are blended with water-soluble cosmetics for skin whose continuous phase is an aqueous phase, such as lotions, essences, gel preparations, oil-in-water emulsion preparations, There is a problem that the active physiologically active substance is likely to leak out and the function of the original liposome cannot be fully exhibited.
従来より、リポソーム内からの生理活性物質の漏れ出しを抑制する成分として、コレステロールなどのステロール類が知られ、これら成分を用いてリポソーム自体の安定性を高める試みもなされている。例えば、リン脂質、ステロール、特定のＨＬＢのポリオキシエチレンステロールエーテル、多価アルコールおよび水を含有するリポソーム（例えば、特許文献４を参照）、リン脂質、コレステロールおよび／又はフィトステロール、白金族金属コロイドおよび水を含有するリポソーム組成物（例えば、特許文献５を参照）などが提案されている。 Conventionally, sterols such as cholesterol are known as components for suppressing leakage of physiologically active substances from liposomes, and attempts have been made to increase the stability of liposomes themselves using these components. For example, phospholipids, sterols, polyoxyethylene sterol ethers of certain HLBs, liposomes containing polyhydric alcohols and water (see, for example, US Pat. No. 6,057,099), phospholipids, cholesterol and / or phytosterols, platinum group metal colloids and A liposome composition containing water (see, for example, Patent Document 5) has been proposed.
これらステロール類の添加によって、ある程度、リポソーム内からの水溶性の生理活性物質の漏れ出しを相転移温度以上では抑制することはできるものの、相転移温度以下においては逆に漏れ出しを促してしまう。また、リポソーム膜自体は相転移温度以下においてもほとんど柔らかくならないために、本来のリポソームの機能、即ち、経皮吸収性を高める効果を十分に発揮させることに劣るといった問題がある。よって、リポソームの機能を十分に発揮させるためには、リポソーム膜を柔軟にして経皮吸収性を高めなければならない。しかしながら、リポソーム膜の柔軟性を高めると、リポソーム自体の保存安定性に劣り、皮膚用水溶性化粧料の製剤中において漏出抑制できないといった問題がある。そのため、リポソーム膜が柔軟であるリポソームを製剤中に配合することは困難であった。 Although the addition of these sterols can suppress the leakage of the water-soluble physiologically active substance from the liposome to some extent above the phase transition temperature, the leakage is promoted below the phase transition temperature. Further, since the liposome membrane itself is hardly soft even at a temperature lower than the phase transition temperature, there is a problem that it is inferior in sufficiently exhibiting the original function of the liposome, that is, the effect of enhancing transdermal absorbability. Therefore, in order to fully exhibit the function of the liposome, the liposome membrane must be made flexible to enhance the transdermal absorbability. However, when the flexibility of the liposome membrane is increased, the storage stability of the liposome itself is poor, and there is a problem that leakage cannot be suppressed in the preparation of the water-soluble cosmetic for skin. For this reason, it has been difficult to incorporate liposomes having a flexible liposome membrane into the preparation.
本発明は、前記従来技術に鑑みてなされたものであり、リポソーム膜の柔軟性が高いにもかかわらず、リポソームに内包させた水溶性の生理活性物質の漏れ出しを抑制することのできるリポソーム含有組成物、並びに、該組成物を配合してなる皮膚用水溶性化粧料を提供することを課題とする。 The present invention has been made in view of the above prior art, and contains a liposome capable of suppressing leakage of a water-soluble physiologically active substance encapsulated in the liposome, despite the high flexibility of the liposome membrane. It is an object of the present invention to provide a composition and a water-soluble cosmetic for skin obtained by blending the composition.
即ち、本発明は、
〔１〕皮膚用水溶性化粧料に配合される組成物であって、（Ａ）リン脂質、（Ｂ）水溶性の生理活性物質、並びに（Ｃ）分岐型高級アルコールからなり、（Ｃ）成分が、総炭素数２０〜２４の分岐型高級アルコールであるリポソームを含有してなる組成物、
〔２〕（Ａ）成分が、水素添加リン脂質である前記〔１〕に記載の組成物、
〔３〕（Ａ）成分、（Ｂ）成分および（Ｃ）成分の含有量は、下記含有質量比を満たす前記〔１〕又は〔２〕に記載の組成物、
（Ｃ）成分／（（Ａ）成分＋（Ｂ）成分）＝０．０１〜０．７、並びに
〔４〕前記〔１〕〜〔３〕の何れかに記載の組成物を配合してなる皮膚用水溶性化粧料
に関する。
That is, the present invention
[1] A composition formulated in a water-soluble cosmetic skin, (A) a phospholipid, Ri Do from (B) water-soluble physiologically active substance, and (C) branched higher alcohols, (C) component but compositions comprising Oh Ru liposomes branched higher alcohols having a total carbon number of 20-24,
[2] The composition according to [1], wherein the component (A) is a hydrogenated phospholipid,
[3] The composition according to [1] or [2], wherein the content of the component (A), the component (B), and the component (C) satisfies the following content mass ratio :
Component (C) / (Component (A) + Component (B)) = 0.01 to 0.7, and [4] A composition according to any one of [1] to [3] is blended. The present invention relates to a water-soluble cosmetic for skin.
本発明のリポソームが含有される組成物は、リポソーム膜の柔軟性が高いにもかかわらず、内包した水溶性の生理活性物質のリポソームからの漏れ出しを抑制するという効果を奏する。また、漏れ出し抑制効果に優れていることから、皮膚用水溶性化粧料にリポソームを安定に配合することができるという効果を奏する。 The composition containing the liposome of the present invention has an effect of suppressing leakage of the encapsulated water-soluble physiologically active substance from the liposome, despite the high flexibility of the liposome membrane. Moreover, since it is excellent in the leak-out suppression effect, there exists an effect that a liposome can be mix | blended stably with the water-soluble cosmetics for skin.
本発明の皮膚用水溶性化粧料に配合される組成物は、（Ａ）リン脂質、（Ｂ）水溶性の生理活性物質、並びに（Ｃ）分岐型高級アルコールからなるリポソームを含有してなるものである。 The composition blended in the water-soluble cosmetic for skin of the present invention comprises (A) a phospholipid, (B) a water-soluble physiologically active substance, and (C) a liposome comprising a branched higher alcohol. is there.
（Ａ）成分のリン脂質とは、リン酸残基を含む複合脂質であって、本発明においてはリポソームを形成する成分である。用いられる（Ａ）成分としては、天然リン脂質、合成リン脂質、天然由来のリン脂質の不飽和炭素鎖を水素により飽和とした水素添加リン脂質などが挙げられる。具体的には、例えば、ホスファチジルコリン、ホスファチジルエタノールアミン、ホスファチジルセリン、ホスファチジルイノシトール、リゾホスファチジルコリン、スフィンゴミエリン、卵黄レシチン、大豆レシチンなどの天然リン脂質；ジラウロイルホスファチジルコリン、ジミリストイルホスファチジルコリン、ジパルミトイルホスファチジルコリン、ジステアロイルホスファチジルコリン、ジオレオイルホスファチジルコリン、パルミトイル・オレオイルホスファチジルコリンなどの合成リン脂質；水素添加大豆レシチン、水素添加卵黄レシチン、水素添加ホスファチジルコリン、水素添加ホスファチジルセリンなどの水素添加リン脂質などを例示することができる。これら（Ａ）成分は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。好適な（Ａ）成分としては、保存安定性に優れる観点から、水素添加リン脂質を用いることが好ましく、中でも、水素添加大豆レシチンを用いることがより好ましい。 The (A) component phospholipid is a complex lipid containing a phosphate residue, and in the present invention, is a component that forms a liposome. Examples of the component (A) used include natural phospholipids, synthetic phospholipids, and hydrogenated phospholipids in which unsaturated carbon chains of naturally derived phospholipids are saturated with hydrogen. Specifically, for example, natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, lysophosphatidylcholine, sphingomyelin, egg yolk lecithin, soybean lecithin; dilauroyl phosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, Examples include synthetic phospholipids such as phosphatidylcholine, dioleoylphosphatidylcholine, palmitoyl oleoylphosphatidylcholine; hydrogenated phospholipids such as hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, hydrogenated phosphatidylcholine, and hydrogenated phosphatidylserine. These (A) components may be used individually by 1 type, and can also be used in combination of 2 or more type as appropriate. As a suitable component (A), it is preferable to use hydrogenated phospholipid from the viewpoint of excellent storage stability, and hydrogenated soybean lecithin is more preferable.
尚、（Ａ）成分は、市販品をそのまま用いることもできる。水素添加大豆レシチンの市販品としては、例えば、ＣＯＡＴＳＯＭＥ ＮＣ−２１，ＮＣ−６１（商品名，何れも日油社製）；ＮＩＫＫＯＬ レシノールＳ−１０ＥＸ，レシノールＳ−１０Ｅ，レシノールＳ−１０Ｍ（商品名，何れも日光ケミカルズ社製）；ベイシス ＬＳ−６０ＨＲ（商品名，日清オイリオグループ社製）などを例示することができる。 In addition, a commercial item can also be used for (A) component as it is. As a commercial item of hydrogenated soybean lecithin, for example, COATSOME NC-21, NC-61 (trade name, all manufactured by NOF Corporation); NIKKOL Resinol S-10EX, Resinol S-10E, Resinol S-10M (trade names) , All manufactured by Nikko Chemicals Co., Ltd.); Basis LS-60HR (trade name, manufactured by Nisshin Oillio Group Co., Ltd.) and the like.
（Ａ）成分の含有量は、所望の効果が充分に付与されるのであれば特に限定されないが、通常、リポソームを形成する観点から、組成物中、０．１質量％以上が好ましく、より好ましくは０．５質量％以上である。また、保存安定性の観点から、１０質量％以下が好ましく、より好ましくは３質量％以下である。これらの観点から、（Ａ）成分の含有量は、好ましくは０．１〜１０質量％、より好ましくは０．５〜３質量％である。 The content of the component (A) is not particularly limited as long as the desired effect is sufficiently imparted, but usually 0.1% by mass or more is preferable in the composition from the viewpoint of forming liposomes, and more preferably. Is 0.5% by mass or more. Moreover, from a viewpoint of storage stability, 10 mass% or less is preferable, More preferably, it is 3 mass% or less. From these viewpoints, the content of the component (A) is preferably 0.1 to 10% by mass, more preferably 0.5 to 3% by mass.
（Ｂ）成分の水溶性の生理活性物質は、上記（Ａ）成分により形成されるリポソームに内包される成分であり、皮膚および人体に対して安全なものであれば特に限定されないが、保湿剤、抗炎症剤、美白剤、細胞賦活剤の群から選ばれる少なくとも１種の水溶性の生理活性物質を用いることが好ましい。 The water-soluble physiologically active substance of the component (B) is a component encapsulated in the liposome formed by the component (A) and is not particularly limited as long as it is safe for the skin and the human body. It is preferable to use at least one water-soluble physiologically active substance selected from the group consisting of an anti-inflammatory agent, a whitening agent, and a cell activator.
具体的な水溶性の生理活性物質としては、例えば、アルテア根エキス、ウイキョウエキス、海藻エキス（褐藻、紅藻、緑藻）、キュウリエキス、キウイエキス、ジオウエキス、シラカバ樹皮エキス、ゼニアオイエキス、タイソウエキス、トウヒエキス、マロニエエキス、メリッサエキス、ユキノシタエキス、加水分解シルクエキス、牛乳糖タンパク、ヒアルロン酸又はヒアルロン酸誘導体、ローヤルゼリーエキスなどの保湿剤；ビルベリー葉エキス、キダチアロエエキス、ウコンエキス、オレンジエキス、グリチルリチン酸ジカリウムおよびその誘導体、カノコソウエキス、カモミラエキス、カワラヨモギエキス、クチナシエキス、コメヌカエキス、サボンソウエキス、シコンエキス、スイカズラエキス、セイヨウキズタエキス、センキュウエキス、クワエキス、タイムエキス、トウガラシエキス、トウニンエキス、ブドウ葉エキス、ベニバナエキス、セイヨウハッカエキス、マツエキス、モモ葉エキス、ユーカリエキス、リンゴエキス、ローマカミツレエキスなどの抗炎症剤；アスコルビン酸グルコシドなどのビタミンＣ誘導体、アルブチンなどの美白剤；アミノカプロン酸、パンテノールなどの細胞賦活剤などを例示することができる。これら（Ｂ）成分は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。 Specific water-soluble physiologically active substances include, for example, Altea root extract, fennel extract, seaweed extract (brown algae, red algae, green algae), cucumber extract, kiwi extract, diou extract, birch bark extract, mallow mushroom extract, typhoid extract, Moisturizers such as spruce extract, maroni extract, melissa extract, yukinosita extract, hydrolyzed silk extract, milk glycoprotein, hyaluronic acid or hyaluronic acid derivative, royal jelly extract; bilberry leaf extract, kidachi aloe extract, turmeric extract, orange extract, glycyrrhizic acid Dipotassium and its derivatives, valerian extract, chamomile extract, kawara mugwort extract, gardenia extract, rice bran extract, red snapper extract, coconut extract, honeysuckle extract, citrus extract, nematode Anti-inflammatory agents such as kiss, mulberry extract, thyme extract, pepper extract, tonin extract, grape leaf extract, safflower extract, mint extract, pine leaf extract, peach leaf extract, eucalyptus extract, apple extract, roman chamomile extract; vitamins such as glucoside ascorbic acid Examples thereof include whitening agents such as C derivatives and arbutin; cell activators such as aminocaproic acid and panthenol. These (B) components may be used individually by 1 type, and can also be used in combination of 2 or more types as appropriate.
（Ｂ）成分の含有量は、リポソームに内包されて、水溶性の生理活性物質の効果が十分に発揮される量であれば特に限定されないが、（Ａ）成分との質量含有比が、（Ｂ）成分／（Ａ）成分＝０．０１〜１の範囲となるように含有させることが好ましく、より好ましくは０．０２〜０．５である。質量含有比が０．０１未満の場合、水溶性の生理活性物質の効果が十分に発揮されないために好ましくない。また、質量含有比が１よりも多い場合、リポソームの凝集、沈殿が生じるために好ましくない。 The content of the component (B) is not particularly limited as long as the effect of the water-soluble physiologically active substance is sufficiently exhibited when encapsulated in the liposome, but the mass content ratio with the component (A) is ( It is preferable to contain so that it may become the range of B) component / (A) component = 0.01-1, More preferably, it is 0.02-0.5. When the mass content ratio is less than 0.01, the effect of the water-soluble physiologically active substance is not sufficiently exhibited, which is not preferable. In addition, when the mass content ratio is more than 1, it is not preferable because aggregation and precipitation of liposomes occur.
本発明においては、後述する（Ｃ）成分の分岐型高級アルコールを配合することで、リポソーム膜の柔軟性が高いにもかかわらず、内包した水溶性の生理活性物質のリポソームからの漏れ出しを抑制することができる。用いられる分岐型高級アルコールは、所望の効果が十分に発揮されるのであれば特に限定されないが、例えば、総炭素数１４〜３０の分岐型の高級アルコールが挙げられる。具体的には、イソステアリルアルコール、ヘキシルデカノール、オクチルデカノール、オクチルドデカノール、デシルテトラデカノール、イソヘキサコサノール、イソオクタコサノール、イソミリシルアルコールなどを例示することができる。これら（Ｃ）成分は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。好適な（Ｃ）成分としては、リポソーム膜を柔軟にする観点、並びに、漏れ出しを抑制する観点から、総炭素数２０〜２４の分岐型高級アルコールを用いることが好ましく、中でも、オクチルドデカノール、デシルテトラデカノールを用いることがより好ましい。 In the present invention, by incorporating a branched higher alcohol as the component (C) described later, the leakage of the encapsulated water-soluble physiologically active substance from the liposome is suppressed despite the high flexibility of the liposome membrane. can do. The branched higher alcohol used is not particularly limited as long as the desired effect is sufficiently exhibited, and examples thereof include branched higher alcohols having a total carbon number of 14 to 30. Specific examples include isostearyl alcohol, hexyl decanol, octyl decanol, octyl decanol, decyl tetradecanol, isohexacosanol, isooctacosanol, and isomycyl alcohol. These (C) components may be used singly or in appropriate combination of two or more. As a suitable component (C), it is preferable to use a branched higher alcohol having a total carbon number of 20 to 24 from the viewpoint of softening the liposome membrane and suppressing leakage. Among them, octyldodecanol, It is more preferable to use decyltetradecanol.
尚、（Ｃ）成分は、市販品をそのまま用いることもできる。オクチルドデカノールの市販品としては、例えば、カルコール２００ＧＤ（商品名，花王社製）などを例示することができる。デシルテトラデカノールの市販品としては、例えば、リソノール ２４ＳＰ（商品名，高級アルコール工業社製）などを例示することができる。 In addition, a commercial item can also be used for (C) component as it is. As a commercial item of octyldodecanol, for example, Calcoal 200GD (trade name, manufactured by Kao Corporation) can be exemplified. As a commercial item of decyltetradecanol, for example, Risonol 24SP (trade name, manufactured by Higher Alcohol Industry Co., Ltd.) can be exemplified.
（Ｃ）成分の含有量は、リポソームに配向されてリポソーム膜が柔軟となる量、並びに、リポソームに内包されている水溶性の生理活性物質の漏れ出しを抑制することができる量であれば特に限定されないが、（Ａ）成分との質量含有比が、（Ｃ）成分／（Ａ）成分＝０．０１〜１の範囲となるように含有させることが好ましく、より好ましくは０．０５〜０．５である。質量含有比が０．０１未満の場合、リポソーム膜の柔軟性に劣るのみならず、水溶性の生理活性物質の漏れ出し抑制効果を十分に発揮できないために好ましくない。また、質量含有比が１よりも多い場合、リポソームの形態を維持できないために好ましくない。 The content of the component (C) is an amount that makes the liposome membrane flexible by being oriented in the liposome, and an amount that can suppress the leakage of the water-soluble physiologically active substance contained in the liposome. Although not limited, it is preferable to make it contain so that mass content ratio with (A) component may become the range of (C) component / (A) component = 0.01-1, More preferably, it is 0.05-0. .5. When the mass content ratio is less than 0.01, not only the flexibility of the liposome membrane is inferior but also the effect of inhibiting leakage of a water-soluble physiologically active substance cannot be sufficiently exhibited, which is not preferable. Moreover, when the mass content ratio is more than 1, it is not preferable because the form of the liposome cannot be maintained.
上記した（Ａ）〜（Ｃ）成分により形成されるリポソームの平均粒子径は、特に限定されないが、内包した水溶性の生理活性物質の漏れ出しを抑制すると共に、製剤中での凝集、沈殿を抑制して安定性を付与する観点から、２０〜３００ｎｍの範囲内とすることが好ましく、より好ましくは３０〜２００ｎｍである。尚、本発明のリポソームの平均粒子径とは、ＥＬＳ−８０００（大塚電子社製）を用いて、積算回数１００回で測定したときの値であるが、これら測定条件のみに限定されるものでない。 The average particle size of the liposome formed by the above-described components (A) to (C) is not particularly limited, but it suppresses leakage of the encapsulated water-soluble physiologically active substance and aggregates and precipitates in the preparation. From the viewpoint of suppressing and imparting stability, it is preferably in the range of 20 to 300 nm, more preferably 30 to 200 nm. In addition, although the average particle diameter of the liposome of the present invention is a value measured with ELS-8000 (manufactured by Otsuka Electronics Co., Ltd.) at a total number of 100 times, it is not limited only to these measurement conditions. .
また、上記した（Ａ）成分、（Ｂ）成分および（Ｃ）成分の含有量は、リポソームの保存安定性を高める観点から、下記含有質量比、
（Ｃ）成分／（（Ａ）成分＋（Ｂ）成分）＝０．０１〜０．７
の範囲を満たすことが好ましく、０．０２〜０．５の範囲を満たすことがより好ましい。含有質量比が０．０１未満の場合、水溶性の生理活性物質の効果が十分に発揮されないために好ましくない。また、０．７よりも大きい場合、リポソームの凝集、沈殿が生じるために好ましくない。
In addition, the content of the component (A), the component (B), and the component (C) described above is from the viewpoint of enhancing the storage stability of the liposome,
(C) component / ((A) component + (B) component) = 0.01-0.7
It is preferable to satisfy | fill the range of 0.02, and it is more preferable to satisfy | fill the range of 0.02-0.5. When the content mass ratio is less than 0.01, the effect of the water-soluble physiologically active substance is not sufficiently exhibited, which is not preferable. Moreover, when larger than 0.7, since aggregation and precipitation of a liposome arise, it is unpreferable.
本発明のリポソームを含有する組成物を調製するためには、溶剤として多価アルコールが用いられる。具体的には、例えば、エチレングリコール、ジエチレングリコール、トリエチレングリコール、ポリエチレングリコール、プロピレングリコール、ジプロピレングリコール、イソプレングリコール、１，３−ブチレングリコール、グリセリン、濃グリセリン、ジグリセリン、ポリグリセリンなどを例示することができる。これら成分は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。 In order to prepare the composition containing the liposome of the present invention, a polyhydric alcohol is used as a solvent. Specific examples include ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, isoprene glycol, 1,3-butylene glycol, glycerin, concentrated glycerin, diglycerin, polyglycerin and the like. be able to. One of these components may be used alone, or two or more thereof may be used in appropriate combination.
溶剤の含有量は、所望の効果が充分に付与されるのであれば特に限定されないが、通常、リポソーム調製時の溶解性の観点から、組成物中、１質量％以上が好ましく、より好ましくは２質量％以上である。また、保存安定性の観点から、５０質量％以下が好ましく、より好ましくは３０質量％以下である。これらの観点から、溶剤の含有量は、好ましくは１〜５０質量％、より好ましくは２〜３０質量％である。 The content of the solvent is not particularly limited as long as the desired effect is sufficiently imparted, but is usually preferably 1% by mass or more, more preferably 2% in the composition from the viewpoint of solubility during liposome preparation. It is at least mass%. Moreover, from a viewpoint of storage stability, 50 mass% or less is preferable, More preferably, it is 30 mass% or less. From these viewpoints, the content of the solvent is preferably 1 to 50% by mass, more preferably 2 to 30% by mass.
リポソームを含有する組成物の製造方法は、公知の方法を用いて製造することができれば特に限定されないが、好ましくは、以下の製造方法を例示することができる。 Although the manufacturing method of the composition containing a liposome is not specifically limited if it can be manufactured using a well-known method, Preferably, the following manufacturing methods can be illustrated.
始めに、溶剤に（Ａ）成分および（Ｃ）成分を加え、７０〜９０℃の温度範囲で均一溶解して混合物（１）を得る。次いで、溶剤に（Ｂ）成分を加え、７０〜９５℃の温度範囲で均一溶解した混合物（２）を、先に調製した混合物（１）に８０℃以上で加え混合する。均一に混合後、８０℃以上に加温した精製水を加え、ホモミキサー（Ｔ．Ｋ．ロボミックス，特殊機化工業社製）を用いて、６０００ｒｐｍ、５分間攪拌する。このような製造工程により、本発明のリポソームを含有する組成物を調製することができる。 First, the component (A) and the component (C) are added to a solvent, and uniformly dissolved in a temperature range of 70 to 90 ° C. to obtain a mixture (1). Next, the component (B) is added to the solvent, and the mixture (2) uniformly dissolved in the temperature range of 70 to 95 ° C. is added to the previously prepared mixture (1) at 80 ° C. or more and mixed. After uniformly mixing, purified water heated to 80 ° C. or higher is added, and the mixture is stirred at 6000 rpm for 5 minutes using a homomixer (TK Robotics, manufactured by Tokushu Kika Kogyo Co., Ltd.). By such a production process, a composition containing the liposome of the present invention can be prepared.
また、本発明においては、より微細なリポソームとするために、高圧ホモジナイザー（マイクロフルイダイザーＭ−１１０−Ｅ／Ｈ，マイクロフルイディックス社製）又は精密乳化分散機（クレアミックス，エム・テクニック社製）を用いて微細化を施しても良い。 In the present invention, in order to obtain finer liposomes, a high-pressure homogenizer (Microfluidizer M-110-E / H, manufactured by Microfluidics) or a precision emulsifier / disperser (Claremix, manufactured by M Technique) ) May be used.
次に、本発明のリポソームを含有する組成物が配合される皮膚用水溶性化粧料について説明する。本発明の皮膚用水溶性化粧料とは、化粧水、エッセンス、ジェル製剤、水中油型乳化製剤などの連続相が水相である皮膚用の化粧料のことを言う。 Next, the water-soluble cosmetic for skin to which the composition containing the liposome of the present invention is blended will be described. The water-soluble cosmetic for skin of the present invention refers to a cosmetic for skin whose continuous phase is an aqueous phase such as lotion, essence, gel preparation, oil-in-water emulsion preparation and the like.
本発明の皮膚用水溶性化粧料を調製する場合、リポソームの保存安定性を損なわない範囲であれば、通常化粧品に用いられる成分、例えば、高級アルコール、脂肪酸、油脂、エステル油、シリコーン油などの油剤；非イオン性界面活性剤、低級アルコール、保湿剤、金属封鎖剤、防腐剤、香料、ｐＨ調整剤、精製水などを目的に応じて適宜配合することができる。 When preparing the water-soluble cosmetic for skin of the present invention, components that are usually used in cosmetics, for example, higher alcohols, fatty acids, oils, fats, ester oils, silicone oils, etc., as long as the storage stability of the liposome is not impaired A nonionic surfactant, a lower alcohol, a humectant, a metal sequestering agent, a preservative, a fragrance, a pH adjuster, purified water and the like can be appropriately blended depending on the purpose.
用いられる油剤の具体例としては、例えば、ラウリルアルコール、ミリスチルアルコール、セチルアルコール、ステアリルアルコール、オレイルアルコール、ラノリンアルコール、ベヘニルアルコール、セトステアリルアルコールなどの高級アルコール；ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、オレイン酸、ベヘニン酸、ウンデシレン酸、ラノリン酸、イソステアリン酸などの脂肪酸；ヤシ油、パーム油、水素添加パーム油、アボカド油、ゴマ油、オリーブ油、ククイナッツ油、ブドウ粒子油、サフラワー油、アーモンド油、トウモロコシ油、綿実油、ヒマワリ種子油、ブドウ種子油、ヘーゼルナッツ油、マカデミアナッツ油、メドウフォーム油、ローズヒップ油などの油脂；オレイン酸エチル、ミリスチン酸イソプロピル、パルミチン酸イソプロピル、ミリスチン酸ミリスチル、パルミチン酸セチル、オレイン酸オレイル、ミリスチン酸オクチルドデシル、オレイン酸オクチルドデシル、イソステアリン酸エチル、イソステアリン酸イソプロピル、２−エチルヘキサン酸セチル、２−エチルヘキサン酸セトステアリル、トリ２−エチルヘキサン酸グリセリル、トリ（カプリル・カプリン酸）グリセリル、トリイソパルミチン酸グリセリル、テトラ２−エチルヘキサン酸ペンタエリスリトール、オクタン酸イソセチル、オクタン酸イソステアリル、イソステアリン酸イソセチル、イソステアリン酸オクチルドデシル、ジメチルオクタン酸オクチルドデシルなどのエステル油；メチルポリシロキサン、高重合メチルポリシロキサン、メチルフェニルポリシロキサン、オクタメチルトリシロキサン、デカメチルテトラシロキサン、オクタメチルシクロテトラシロキサン、デカメチルシクロペンタシロキサン、ドデカメチルシクロヘキサシロキサン、メチルシクロポリシロキサン、アルコール変性シリコーン、アルキル変性シリコーン、アミノ変性シリコーン、エポキシ変性シリコーンなどのシリコーン油などを例示することができる。これら油剤は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。 Specific examples of the oil used include higher alcohols such as lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, lanolin alcohol, behenyl alcohol, cetostearyl alcohol; lauric acid, myristic acid, palmitic acid, stearic acid Fatty acids such as oleic acid, behenic acid, undecylenic acid, lanolinic acid, isostearic acid; coconut oil, palm oil, hydrogenated palm oil, avocado oil, sesame oil, olive oil, kukui nut oil, grape particle oil, safflower oil, almond oil Oils such as corn oil, cottonseed oil, sunflower seed oil, grape seed oil, hazelnut oil, macadamia nut oil, meadow foam oil, rosehip oil; ethyl oleate, isopropyl myristate , Isopropyl palmitate, myristyl myristate, cetyl palmitate, oleyl oleate, octyldodecyl myristate, octyldodecyl oleate, ethyl isostearate, isopropyl isostearate, cetyl 2-ethylhexanoate, cetostearyl 2-ethylhexanoate, Glyceryl tri-2-ethylhexanoate, glyceryl tri (capryl / caprate), glyceryl triisopalmitate, pentaerythritol tetra-2-ethylhexanoate, isocetyl octoate, isostearyl octoate, isocetyl isostearate, octyldodecyl isostearate, Ester oil such as octyldodecyl dimethyloctanoate; methylpolysiloxane, highly polymerized methylpolysiloxane, methylphenylpolysiloxane Octamethyltrisiloxane, decamethyltetrasiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, methylcyclopolysiloxane, alcohol-modified silicone, alkyl-modified silicone, amino-modified silicone, epoxy-modified silicone, etc. A silicone oil etc. can be illustrated. These oil agents may be used alone or in combination of two or more.
用いられる非イオン性界面活性剤としては、例えば、グリセリン脂肪酸エステル、グリセリン脂肪酸エステルの酸化エチレン縮合物、ポリアルキレングリコール脂肪酸エステル、ソルビタン脂肪酸エステル、ソルビタン脂肪酸エステルの酸化エチレン縮合物などの脂肪酸エステル型非イオン性界面活性剤の他、ポリオキシアルキレンアルキルエーテル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンヒマシ油、ポリオキシエチレンラノリンなどが挙げられる。これら非イオン性界面活性剤は、１種を単独で用いてもよく、２種以上を適宜組み合わせて用いることもできる。 Examples of the nonionic surfactant used include fatty acid ester-type non-ionic surfactants such as glycerin fatty acid ester, ethylene oxide condensate of glycerin fatty acid ester, polyalkylene glycol fatty acid ester, sorbitan fatty acid ester, and ethylene oxide condensate of sorbitan fatty acid ester. In addition to ionic surfactants, polyoxyalkylene alkyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, polyoxyethylene lanolin and the like can be mentioned. These nonionic surfactants can be used singly or in appropriate combination of two or more.
グリセリン肪酸エステルとしては、本発明においては、グリセリン脂肪酸エステルおよびポリグリセリン脂肪酸エステルのいずれをも意味し、具体的には、モノカプリル酸グリセリル、モノカプリン酸グリセリル、モノラウリン酸グリセリル、モノミリスチン酸グリセリル、モノパルミチン酸グリセリル、モノステアリン酸グリセリル、モノイソステアリン酸グリセリル、モノベヘン酸グリセリル、モノオレイン酸グリセリル、モノエルカ酸グリセリル、セスキオレイン酸グリセリル、ジステアリン酸グリセリル、ジイソステアリン酸グリセリル、ジアラキン酸グリセリルなどのグリセリン脂肪酸エステル；モノカプリル酸ジグリセリル、モノカプリル酸デカグリセリル、モノカプリン酸ヘキサグリセリル、モノラウリン酸テトラグリセリル、モノラウリン酸ヘキサグリセリル、モノラウリン酸デカグリセリル、モノラウリン酸ポリ（４〜１０）グリセリル、モノミリスチン酸デカグリセリル、モノステアリン酸デカグリセリル、モノイソステアリン酸デカグリセリル、モノステアリン酸ポリ（２〜１０）グリセリル、モノオレイン酸ジグリセリル、モノオレイン酸ヘキサグリセリル、セスキオレイン酸ジグリセリル、ジイソステアリン酸ポリ（２〜１０）グリセリル、ジステアリン酸ポリ（６〜１０）グリセリル、トリイソステアリン酸ジグリセリル、トリステアリン酸ポリ（１０）グリセリルなどの上記したグリセリン脂肪酸エステルの重合度２〜１０のポリグリセリン脂肪酸エステルを例示することができる。また、グリセリン脂肪酸エステルの酸化エチレン縮合物としては、モノステアリン酸ポリオキシエチレングリセリル、モノオレイン酸ポリオキシエチレングリセリルなどを例示することができる。 In the present invention, glycerin fatty acid ester means both glycerin fatty acid ester and polyglycerin fatty acid ester. Specifically, glyceryl monocaprylate, glyceryl monocaprate, glyceryl monolaurate, glyceryl monomyristate Glyceryl fatty acid esters such as glyceryl monopalmitate, glyceryl monostearate, glyceryl monoisostearate, glyceryl monobehenate, glyceryl monooleate, glyceryl monoerucate, glyceryl sesquioleate, glyceryl distearate, glyceryl diisostearate, glyceryl diarachiate ; Diglyceryl monocaprylate, decaglyceryl monocaprylate, hexaglyceryl monocaprate, tetraglyceryl monolaurate Hexaglyceryl monolaurate, decaglyceryl monolaurate, poly (4-10) glyceryl monolaurate, decaglyceryl monomyristate, decaglyceryl monostearate, decaglyceryl monoisostearate, poly (2-10) glyceryl monostearate, mono Diglyceryl oleate, hexaglyceryl monooleate, diglyceryl sesquioleate, poly (2-10) glyceryl diisostearate, poly (6-10) glyceryl distearate, diglyceryl triisostearate, poly (10) tristearate Examples thereof include polyglycerol fatty acid esters having a polymerization degree of 2 to 10 as described above, such as glyceryl. Examples of the ethylene oxide condensate of glycerol fatty acid ester include polyoxyethylene glyceryl monostearate and polyoxyethylene glyceryl monooleate.
ポリアルキレングリコール脂肪酸エステルとしては、例えば、モノラウリン酸ポリエチレングリコール、モノステアリン酸ポリエチレングリコール、モノイソステアリン酸ポリエチレングリコール、モノオレイン酸ポリエチレングリコール、ジラウリン酸ポリエチレングリコール、ジステアリン酸ポリエチレングリコール、ジイソステアリン酸ポリエチレングリコール、ジオレイン酸ポリエチレングリコールなどのポリエチレングリコール脂肪酸エステル；モノステアリン酸プロピレングリコール、モノラウリン酸プロピレングリコール、モノオレイン酸プロピレングリコールなどのプロピレングリコール脂肪酸エステルなどを例示することができる。 Examples of the polyalkylene glycol fatty acid ester include polyethylene glycol monolaurate, polyethylene glycol monostearate, polyethylene glycol monoisostearate, polyethylene glycol monooleate, polyethylene glycol dilaurate, polyethylene glycol distearate, polyethylene glycol diisostearate, and dioleic acid. Examples include polyethylene glycol fatty acid esters such as polyethylene glycol; propylene glycol fatty acid esters such as propylene glycol monostearate, propylene glycol monolaurate, and propylene glycol monooleate.
ソルビタン脂肪酸エステルとしては、例えば、モノオレイン酸ソルビタン、モノステアリン酸ソルビタン、モノイソステアリン酸ソルビタン、モノパルミチン酸ソルビタン、モノラウリン酸ソルビタン、トリオレイン酸ソルビタン、トリステアリン酸ソルビタン、セスキステアリン酸ソルビタン、セスキオレイン酸ソルビタン、セスキイソステアリン酸ソルビタン、ヤシ油脂肪酸ソルビタンなどのソルビタン脂肪酸エステルを例示することができる。また、ソルビタン脂肪酸エステルの酸化エチレン縮合物としては、モノラウリン酸ポリオキシエチレンソルビタン、モノパルミチン酸ポリオキシエチレンソルビタン、モノステアリン酸ポリオキシエチレンソルビタン、モノオレイン酸ポリオキシエチレンソルビタン、モノイソステアリン酸ポリオキシエチレンソルビタン、モノヤシ油脂肪酸ポリオキシエチレンソルビタン、トリステアリン酸ポリオキシエチレンソルビタン、トリオレイン酸ポリオキシエチレンソルビタンなどを例示することができる。 Examples of sorbitan fatty acid esters include sorbitan monooleate, sorbitan monostearate, sorbitan monoisostearate, sorbitan monopalmitate, sorbitan monolaurate, sorbitan trioleate, sorbitan tristearate, sorbitan sesquistearate, sesquioleate Examples include sorbitan fatty acid esters such as sorbitan, sorbitan sesquiisostearate, and coconut oil fatty acid sorbitan. Examples of the ethylene oxide condensate of sorbitan fatty acid ester include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene monoisostearate Examples include sorbitan, mono coconut oil fatty acid polyoxyethylene sorbitan, polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan trioleate, and the like.
ポリオキシアルキレンアルキルエーテルとしては、例えば、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンセチルエーテル、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンオレイルエーテル、ポリオキシエチレンポリオキシプロピレンラウリルエーテル、ポリオキシプロピレンセチルエーテル、ポリオキシプロピレンイソセチルエーテル、ポリオキシプロピレンステアリルエーテル、ポリオキシプロピレンオレイルエーテルなどを例示することができる。 Examples of the polyoxyalkylene alkyl ether include polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene polyoxypropylene lauryl ether, polyoxypropylene cetyl ether, Examples thereof include oxypropylene isocetyl ether, polyoxypropylene stearyl ether, and polyoxypropylene oleyl ether.
本発明の皮膚用水溶性化粧料の形態は、リポソームが安定に配合されるのであれば特に限定されず、液状、ジェル状、乳液状、クリーム状などの種々の形態をとり得ることができる。中でも、本発明のリポソームを含有する組成物は、リポソームに内包される水溶性の生理活性物質の漏れ出しを抑制することから、通常、水溶性の生理活性物質を内包するリポソームの配合が困難とされる、化粧水、エッセンス、ジェル製剤、水中油型乳化製剤などの連続相が水相である製剤であっても安定に配合することができるものである。 The form of the water-soluble cosmetic for skin of the present invention is not particularly limited as long as the liposome is stably blended, and can take various forms such as liquid, gel, emulsion and cream. Among these, since the composition containing the liposome of the present invention suppresses leakage of the water-soluble physiologically active substance encapsulated in the liposome, it is usually difficult to mix the liposome encapsulating the water-soluble physiologically active substance. Even a preparation in which the continuous phase is an aqueous phase, such as lotion, essence, gel preparation, oil-in-water emulsion preparation, etc., can be stably blended.
以下、本発明を実施例に基づいて更に詳細に説明するが、本発明はこれら実施例にのみ限定されるものではない。尚、配合量は、特記しない限り「質量％」を表す。また、評価はすべて、２３℃、湿度６０％の恒温恒湿の一定条件下で実施した。 EXAMPLES Hereinafter, although this invention is demonstrated further in detail based on an Example, this invention is not limited only to these Examples. The blending amount represents “% by mass” unless otherwise specified. Moreover, all evaluation was implemented on the constant conditions of constant temperature and humidity of 23 degreeC and 60% of humidity.
（試料の調製１）
表１および表２に記した組成に従い、処方例１〜８の各リポソームを常法に準じて調製した。尚、示差走査熱量測定における吸熱ピークの検出限界を考慮して、リポソーム濃度を高くした試料にて下記評価に供した。
(Sample preparation 1)
According to the composition described in Table 1 and Table 2, each liposome of the formulation examples 1-8 was prepared according to the conventional method. In consideration of the detection limit of the endothermic peak in differential scanning calorimetry, the sample was subjected to the following evaluation using a sample with a high liposome concentration.
（試験例１：リポソーム膜の柔軟性試験）
処方例１〜８の各リポソームをアロジン処理済みアルミニウム製密封容器（エスアイアイ・ナノテクノロジー社製）に適量封入し、示差走査熱量測定（ＤＳＣ；ＥＸＳＴＡＲ６０００：エスアイアイ・ナノテクノロジー社製）を用いて２０℃〜８０℃の範囲で５℃／ｍｉｎの条件にて測定し、相転移温度を求めた。結果を表１および表２に併記する。
(Test Example 1: Liposome membrane flexibility test)
Appropriate amounts of each of the liposomes of Formulation Examples 1 to 8 are sealed in an allodin-treated aluminum sealed container (SII NanoTechnology) and differential scanning calorimetry (DSC; EXSTAR6000: SII NanoTechnology) is used. The phase transition temperature was determined by measurement under the condition of 5 ° C./min in the range of 20 ° C. to 80 ° C. The results are shown in Tables 1 and 2.
本測定では、内包される水溶性の生理活性物質、並びに膜構成成分である水素添加大豆レシチンの疎水基間相互作用における他因子、具体的には、リポソーム含有組成物の調製時に用いる多価アルコールなどの溶剤の影響を取り除くために、溶剤としてクロロホルムを用い、薄膜法にて調製したリポソームの示差走査熱量測定を行った。 In this measurement, the water-soluble physiologically active substance to be encapsulated and other factors in the interaction between hydrophobic groups of hydrogenated soybean lecithin, which is a membrane component, specifically, a polyhydric alcohol used in preparing a liposome-containing composition In order to remove the influence of solvents such as the above, differential scanning calorimetry was performed on liposomes prepared by the thin film method using chloroform as a solvent.
尚、薄膜法とは、リポソーム膜構成成分である（Ａ）成分および（Ｃ）成分を（但し、（Ｃ）成分を含まない場合は（Ａ）成分のみを、また、（Ｃ）成分以外の高級アルコール又はステロール類を含む場合は（Ａ）成分とそれら成分を）クロロホルムに溶解後、ロータリーエバポレーターにて溶媒を留去し、脂質フィルムを作成する。そこへ、精製水に溶解させた（Ｂ）成分を加え、相転移温度（約８０℃）以上に加温後、振とうしてフィルムを剥がし、試料を調製する方法である。 The thin film method refers to components (A) and (C) that are liposome membrane constituents (however, when (C) component is not included, only (A) component is used, and other than (C) component) When higher alcohols or sterols are contained, the component (A) and these components are dissolved in chloroform), and then the solvent is distilled off by a rotary evaporator to prepare a lipid film. In this method, the component (B) dissolved in purified water is added, heated to a phase transition temperature (about 80 ° C.) or higher, and then shaken to peel off the film to prepare a sample.
表１および表２に示す通り、示差走査熱量測定結果から、処方例１〜４のリポソームは、処方例５のリポソームと対比して、膜構成成分である水素添加大豆レシチンの疎水基間相互作用を弱め、リポソーム膜の相転移温度（融点）の低下を引き起こし、リポソーム膜を柔らかくする、即ち、リポソーム膜の柔軟性を高めていることが確認された。 As shown in Tables 1 and 2, from the results of differential scanning calorimetry, the liposomes of Formulation Examples 1 to 4 are compared with the liposomes of Formulation Example 5, and the interaction between hydrophobic groups of hydrogenated soybean lecithin, which is a membrane component It was confirmed that the phase transition temperature (melting point) of the liposome membrane was lowered and the liposome membrane was softened, that is, the flexibility of the liposome membrane was increased.
これに対して、処方例６〜８のリポソームは、処方例５のリポソームの相転移温度と同等、若しくは相転移温度が上昇していることから、リポソーム膜を硬くする、即ち、リポソーム膜の硬化性を高めていることが確認された。 On the other hand, the liposomes of Formulation Examples 6 to 8 are equivalent to the phase transition temperature of the liposome of Formulation Example 5 or the phase transition temperature is increased, so that the liposome membrane is hardened, that is, the liposome membrane is cured. It was confirmed that the sex was improved.
（試料の調製２）
表３および表４に記した組成に従い、処方例９〜１６の各リポソームを先と同様に薄膜法にて調製し、下記試験に供した。結果を表３および表４に併記する。
(Sample preparation 2)
According to the composition described in Table 3 and Table 4, each liposome of Formulation Examples 9 to 16 was prepared by the thin film method in the same manner as described above and subjected to the following test. The results are also shown in Tables 3 and 4.
尚、漏れ出し試験を行うにあたり、（Ｂ）成分である水溶性の生理活性物質の代替として、リポソームに内包される内包物には、水溶性の蛍光薬剤である５，６−カルボキシフルオレセインを用いた。より具体的には、５，６−カルボキシフルオレセイン ３７．８ｇを２０ｍｍｏｌ／Ｌ Ｔｒｉｓ−ＨＣｌバッファー（２．４２ｇを精製水１Ｌに溶解後、ＨＣｌにてｐＨ７．５に調製したもの）に溶解し、ＮａＯＨにてｐＨ７．５に調製したものを調製物１として用いた。また、漏れ出し試験には、内包されなかった調製物１をゲル濾過クロマトグラフィー（Ｓｅｐｈａｄｅｘ Ｇ−５０）にて除去したものを用いた。 In conducting the leakage test, water-soluble fluorescent agent 5,6-carboxyfluorescein is used for inclusion in liposomes as an alternative to the water-soluble physiologically active substance (B). It was. More specifically, 37.8 g of 5,6-carboxyfluorescein was dissolved in 20 mmol / L Tris-HCl buffer (2.42 g dissolved in 1 L of purified water and adjusted to pH 7.5 with HCl), What was adjusted to pH 7.5 with NaOH was used as Preparation 1. Moreover, what removed the preparation 1 which was not included by the gel filtration chromatography (Sephadex G-50) was used for the leak test.
（試験例２：漏れ出し試験）
処方例９〜１６で調製した各リポソームを、４０℃の恒温槽に１時間保管（インキュベート）後、分光蛍光光度計（励起波長：４９０ｎｍ、蛍光波長：５３０ｎｍ）を用いて、内包物（５，６−カルボキシフルオレセイン）の漏れ出しを測定した蛍光強度の値から漏出率（％）を算出し、下記基準に従って評価した。
(Test Example 2: Leakage test)
Each liposome prepared in Formulation Examples 9 to 16 is stored (incubated) in a constant temperature bath at 40 ° C. for 1 hour, and then is used for inclusion (5, excitation wavelength: 490 nm, fluorescence wavelength: 530 nm) using a spectrofluorometer. The leakage rate (%) was calculated from the fluorescence intensity value obtained by measuring leakage of 6-carboxyfluorescein) and evaluated according to the following criteria.
漏出率（％）＝〔（Ｆ２−Ｆ１）／（Ｆ３−Ｆ１）〕×１００
Ｆ１：インキュベート前の蛍光強度
Ｆ２：４０℃にてインキュベート後の蛍光強度
Ｆ３：Ｔｒｉｔｏｎ−Ｘ１００を加え、加熱処理した後の蛍光強度（１００％漏出）
Leakage rate (%) = [(F 2 −F 1 ) / (F 3 −F 1 )] × 100
F 1 : Fluorescence intensity before incubation F 2 : Fluorescence intensity after incubation at 40 ° C. F 3 : Fluorescence intensity after heat treatment by adding Triton-X100 (100% leakage)
＜漏れ出し試験の評価基準＞
○：漏出率（％）が、０％以上２０％未満
△：漏出率（％）が、２０％以上３０％未満
×：漏出率（％）が、３０％以上
<Evaluation criteria for leak test>
○: Leakage rate (%) is 0% or more and less than 20% △: Leakage rate (%) is 20% or more and less than 30% ×: Leakage rate (%) is 30% or more
表３および表４に示す通り、処方例９〜１２のリポソームは、水溶性内包物である５，６−カルボキシフルオレセインの漏れ出しが極めて小さく、漏れ出し抑制効果に優れた効果を奏していることが分かる。一方、処方例１３〜１６のリポソームは、５、６−カルボキシフルオレセインの漏れ出しが著しく促進され、安定性が極めて低く、漏れ出し抑制効果がないことが分かる。 As shown in Table 3 and Table 4, the liposomes of Formulation Examples 9 to 12 have extremely small leakage of 5,6-carboxyfluorescein, which is a water-soluble inclusion, and have an excellent effect of suppressing leakage. I understand. On the other hand, it can be seen that the liposomes of Formulation Examples 13 to 16 significantly promote leakage of 5,6-carboxyfluorescein, have extremely low stability, and have no leakage suppressing effect.
（試料の調製２）
表５に記した組成に従い、実施例１〜４の漏れ出し抑制効果、並びに、リポソーム膜の柔軟性に優れるリポソーム含有組成物を常法に準じて調製した。
(Sample preparation 2)
According to the composition described in Table 5, the liposome-containing composition excellent in the leakage inhibiting effect of Examples 1 to 4 and the flexibility of the liposome membrane was prepared according to a conventional method.
（試料の調製３）
表６に記した組成に従い、実施例１〜４の各リポソーム含有組成物を配合した実施例５〜８の皮膚用水溶性化粧料を常法に準じて調製し、下記評価に供した。尚、実施例５は液状の皮膚用水溶性化粧料、実施例６はジェル状の皮膚用水溶性化粧料、実施例７は乳液状の皮膚用水溶性化粧料、実施例８はクリーム状の皮膚用水溶性化粧料として調製した。
(Sample preparation 3)
According to the composition described in Table 6, the skin water-soluble cosmetics of Examples 5 to 8 blended with the liposome-containing compositions of Examples 1 to 4 were prepared according to a conventional method and subjected to the following evaluation. In addition, Example 5 is a liquid water-soluble cosmetic for skin, Example 6 is a gel-like water-soluble cosmetic for skin, Example 7 is a milky water-soluble cosmetic for skin, and Example 8 is a cream-like water-soluble cosmetic for skin. Prepared as a cosmetic.
（試験例３：保存安定性の評価）
実施例５〜８で得られた試料の製造直後のリポソームの形態を透過型電子顕微鏡により観察した。次いで、各試料を５０ｍＬ容の透明ガラス容器にそれぞれ封入し、４０℃の恒温槽に夫々６週間保存した後のリポソームの形態を透過型電子顕微鏡により再度観察し、以下の評価基準に従って評価した。
尚、透過型電子顕微鏡での観察は、ネガティブ染色法で行った。
(Test Example 3: Evaluation of storage stability)
The form of the liposome immediately after production of the samples obtained in Examples 5 to 8 was observed with a transmission electron microscope. Next, each sample was sealed in a 50 mL clear glass container and stored in a constant temperature bath at 40 ° C. for 6 weeks, and the morphology of the liposomes was observed again with a transmission electron microscope and evaluated according to the following evaluation criteria.
The observation with a transmission electron microscope was carried out by a negative staining method.
＜保存安定性の評価基準＞
○：製造直後と全く変化が認められない（リポソームの形態が崩壊していない）
△：リポソームの形態が一部崩壊している
×：リポソームの形態が全崩壊している
<Evaluation criteria for storage stability>
○: No change is observed immediately after production (the form of the liposome has not collapsed)
Δ: Liposomes are partially disintegrated ×: All liposomes are disintegrated
表６に示された結果から、本願発明のリポソーム含有組成物は、リポソーム膜が柔軟であるにもかかわらず、リポソームに内包した水溶性の生理活性物質の漏れ出しがなく、安定に配合することができることから、種々の剤型の皮膚用水溶性化粧料に配合したとしても、リポソームの長期保存安定性に格段に優れた効果を奏するものであることが分かる。 From the results shown in Table 6, the liposome-containing composition of the present invention should be blended stably without leakage of the water-soluble physiologically active substance encapsulated in the liposome, even though the liposome membrane is flexible. Therefore, it can be seen that even when blended with various dosage forms of water-soluble cosmetics for skin, it has a remarkable effect on the long-term storage stability of liposomes.
Claims (4)
（Ｃ）成分が、総炭素数２０〜２４の分岐型高級アルコールである組成物。 A composition formulated into dermatological water-soluble cosmetic, Ri name contains (A) a phospholipid, (B) a water-soluble physiologically active substance, and (C) liposomes composed of branched higher alcohol,
(C) component, Oh Ru compositions in branched higher alcohols having a total carbon number of 20-24.
（Ｃ）成分／（（Ａ）成分＋（Ｂ）成分）＝０．０１〜０．７(C) component / ((A) component + (B) component) = 0.01-0.7
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010216051A JP5601951B2 (en) | 2010-09-27 | 2010-09-27 | Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010216051A JP5601951B2 (en) | 2010-09-27 | 2010-09-27 | Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012072066A JP2012072066A (en) | 2012-04-12 |
| JP5601951B2 true JP5601951B2 (en) | 2014-10-08 |
Family
ID=46168678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010216051A Active JP5601951B2 (en) | 2010-09-27 | 2010-09-27 | Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5601951B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102104095B1 (en) * | 2016-09-29 | 2020-04-23 | 가부시키가이샤 만다무 | Oil painting cosmetic |
| JP6792632B2 (en) * | 2016-11-18 | 2020-11-25 | 株式会社マンダム | Emulsified cosmetics |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0521562T3 (en) * | 1991-06-26 | 2003-07-14 | Yamanouchi Europ Bv | Vesicles in non-polar media |
| EP1138313A1 (en) * | 2000-03-28 | 2001-10-04 | Primacare S.A. | Proliposomes |
| JP2004168763A (en) * | 2002-10-30 | 2004-06-17 | Dsr Corp | Skin cosmetic |
| JP2007176820A (en) * | 2005-12-27 | 2007-07-12 | Nippon Fine Chem Co Ltd | Powdery phospholipid composition |
-
2010
- 2010-09-27 JP JP2010216051A patent/JP5601951B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012072066A (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2928423T3 (en) | Composition of an oil-in-water type emulsion and procedure for producing the same | |
| KR101868726B1 (en) | Method for producing ceramide dispersion composition | |
| KR101633639B1 (en) | Nano gel emulsion having similar structure with cell membrane using self-assembled gel characteristics and osmetic composition using the same | |
| JP2008184431A (en) | External preparation for skin | |
| KR20150022434A (en) | Preparing methods nano emulsion | |
| JP4731301B2 (en) | Moisturizer and cosmetics containing the same | |
| CN101827578B (en) | Inverted vesicles | |
| JP5495656B2 (en) | Emulsified cosmetic for skin | |
| JP2003212716A (en) | Liquid crystalline emulsion composition | |
| WO2015136784A1 (en) | Ceramide dispersion composition | |
| JP5601951B2 (en) | Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition | |
| KR20220091739A (en) | Translucent nanoemulsion containing natural ceramide and cosmetic composition including the same | |
| EP2520273B1 (en) | Cosmetic preparation | |
| JP5601950B2 (en) | Liposome-containing composition, and water-soluble cosmetic for skin comprising the composition | |
| JP5495255B2 (en) | Liposome-containing composition, and cosmetic for skin comprising the composition | |
| JP5117208B2 (en) | Highly polar oil-containing oil-in-water ultrafine emulsion external preparation and method for producing the oil-in-water ultrafine emulsion external preparation | |
| JP6790710B2 (en) | Ursolic acid-containing liposome dispersion | |
| KR102565630B1 (en) | Cosmetic composition containing phenoxyethanol | |
| JP6941425B2 (en) | A method for preparing a composition that matures the stratum corneum of the skin, and a skin stratum corneum maturating agent. | |
| JP6031182B1 (en) | Method for producing oil-in-water emulsion composition | |
| Syafitri et al. | The effect of surfactant and co-surfactant ratio on physical stability of rice bran oil based-nanoemulsion (organoleptic and pH parameters) | |
| KR102248265B1 (en) | Method for producing ceramide ball with excellent stability and ceramide ball with excellent stability produced by the same method | |
| WO2022102730A1 (en) | Lipid-particle-containing cosmetic composition including phospholipid, and cosmetic quasi-drug | |
| JP2007169174A (en) | O/w type emulsified composition | |
| JP2006282543A (en) | Oil-in-water type microemulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130314 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140318 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140819 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140819 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5601951 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |